() shares rose as it strengthened its worldwide patent protection for lead drug VAL 201 - having been granted a patent by the European office.
Chief operating officer Dr George Morris tells Proactive: ''It's always gratifying to have granted patents rather than just pending patents.''
''On this occasion I think it's particularly important in that all the key markets in which we are currently doing work and are likely to be doing work are now protected and covered for the use and the cancer therapy applications of VAL 201''.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
